Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 10/20 | 0.48 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.47 |
| ▸ | OGA | O60502 | 2/20 | 0.42 |
| ▸ | ACACB | O00763 | 2/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.35 |
| ▸ | WNT3A | P56704 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27046445 | 1.00 | PDE2A (0.48) | PDE2AGPR55OGAACACBKIF11 | |
| SCHEMBL879006 | 0.82 | GPR55 (0.45) | PDE2AGPR55OGAACACBKIF11 | |
| SCHEMBL27043933 | 0.81 | PDE2A (0.47) | PDE2AGPR55OGAACACBKIF11 | |
| SCHEMBL18237188 | 0.80 | PDE2A (0.61) | PDE2AGPR55OGAACACBALDH1A1 | |
| SCHEMBL24494541 | 0.79 | GPR55 (0.43) | PDE2AGPR55OGAACACBKIF11 | |
| SCHEMBL17541572 | 0.79 | PDE2A (0.44) | PDE2AGPR55OGAACACBCTNNB1 | |
| SCHEMBL3669583 | 0.79 | GPR55 (0.43) | PDE2AGPR55OGAACACBKIF11 | |
| SCHEMBL20559520 | 0.79 | GPR55 (0.43) | PDE2AGPR55OGAACACBKIF11 | |
| SCHEMBL6336282 | 0.79 | GPR55 (0.43) | PDE2AGPR55OGAACACBKIF11 | |
| SCHEMBL30687097 | 0.79 | PDE2A (0.44) | PDE2AGPR55OGAACACBCTNNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10259785-B2 | Therapeutic compounds and compositions | EXITHERA PHARMACEUTICALS, INC. (US) | 2019-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10259785-B2 | Therapeutic compounds and compositions | KLK5, KLKB1, KLK2 | PDE2A 624/4885GPR55 2798/4885OGA 2405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.